{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T01:58:26Z","timestamp":1775613506000,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100024932","name":"Children\u2019s Health Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100024932","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-95956-1","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T04:50:51Z","timestamp":1743828651000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Neutralizing antibodies to SARS-CoV-2 variants of concern:\u00a0a pediatric surveillance study"],"prefix":"10.1038","volume":"15","author":[{"given":"Douglas D.","family":"Fraser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devika","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enis","family":"Cela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maitray A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maysaa","family":"Assaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maritza","family":"Quintero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Knauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melina","family":"Bellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Hrek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cruz-Aguado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"issue":"4","key":"95956_CR1","doi-asserted-by":"crossref","first-page":"e0266852","DOI":"10.1371\/journal.pone.0266852","volume":"17","author":"J Perry","year":"2022","unstructured":"Perry, J. et al. Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review. PLoS One. 17 (4), e0266852 (2022).","journal-title":"PLoS One"},{"issue":"1","key":"95956_CR2","doi-asserted-by":"crossref","first-page":"e0029121","DOI":"10.1128\/Spectrum.00291-21","volume":"9","author":"CL Charlton","year":"2021","unstructured":"Charlton, C. L. et al. Pre-Vaccine positivity of SARS-CoV-2 antibodies in Alberta, Canada during the first two waves of the COVID-19 pandemic. Microbiol. Spectr. 9 (1), e0029121 (2021).","journal-title":"Microbiol. Spectr."},{"issue":"9","key":"95956_CR3","doi-asserted-by":"crossref","first-page":"1256e9","DOI":"10.1016\/j.cmi.2020.05.036","volume":"26","author":"KL Chew","year":"2020","unstructured":"Chew, K. L. et al. Clinical evaluation of serological IgG antibody response on the Abbott architect for established SARS-CoV-2 infection. Clin. Microbiol. Infect. 26 (9), 1256e9\u20131256e11 (2020).","journal-title":"Clin. Microbiol. Infect."},{"key":"95956_CR4","doi-asserted-by":"crossref","unstructured":"Bryan, A. et al. Performance characteristics of the Abbott architect SARS-CoV-2 IgG assay and Seroprevalence in Boise, Idaho. J. Clin. Microbiol., 58(8). (2020).","DOI":"10.1128\/JCM.00941-20"},{"issue":"2","key":"95956_CR5","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/jmv.26341","volume":"93","author":"KJ Paiva","year":"2021","unstructured":"Paiva, K. J. et al. Validation and performance comparison of three SARS-CoV-2 antibody assays. J. Med. Virol. 93 (2), 916\u2013923 (2021).","journal-title":"J. Med. Virol."},{"issue":"1","key":"95956_CR6","doi-asserted-by":"crossref","first-page":"4984","DOI":"10.1038\/s41467-021-25312-0","volume":"12","author":"C Feng","year":"2021","unstructured":"Feng, C. et al. Protective humoral and cellular immune responses to SARS-CoV-2 persist up to 1 year after recovery. Nat. Commun. 12 (1), 4984 (2021).","journal-title":"Nat. Commun."},{"issue":"7","key":"95956_CR7","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/cid\/ciab607","volume":"74","author":"L Grandjean","year":"2022","unstructured":"Grandjean, L. et al. Long-Term persistence of Spike protein antibody and predictive modeling of antibody dynamics after infection with severe acute respiratory syndrome coronavirus 2. Clin. Infect. Dis. 74 (7), 1220\u20131229 (2022).","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"95956_CR8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/jpids\/piac012","volume":"11","author":"MS Han","year":"2022","unstructured":"Han, M. S. et al. Antibody responses to SARS-CoV-2 in children with COVID-19. J. Pediatr. Infect. Dis. Soc. 11 (6), 267\u2013273 (2022).","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"95956_CR9","doi-asserted-by":"crossref","unstructured":"Messiah, S. E. et al. Durability of SARS-CoV-2 antibodies from natural infection in children and adolescents. Pediatrics, 149(6). (2022).","DOI":"10.1542\/peds.2021-055505"},{"key":"95956_CR10","doi-asserted-by":"crossref","unstructured":"Messiah, S. E. et al. Long-term immune response to SARS-CoV-2 infection and vaccination in children and adolescents. Pediatr. Res., (2023).","DOI":"10.1038\/s41390-023-02857-y"},{"issue":"11","key":"95956_CR11","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1001\/jamapediatrics.2022.3072","volume":"176","author":"CF Yung","year":"2022","unstructured":"Yung, C. F. et al. Analysis of neutralizing antibody levels in children and adolescents up to 16 months after SARS-CoV-2 infection. JAMA Pediatr. 176 (11), 1142\u20131143 (2022).","journal-title":"JAMA Pediatr."},{"issue":"7","key":"95956_CR12","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/archdischild-2020-320558","volume":"106","author":"T Waterfield","year":"2021","unstructured":"Waterfield, T. et al. Seroprevalence of SARS-CoV-2 antibodies in children: a prospective multicentre cohort study. Arch. Dis. Child. 106 (7), 680\u2013686 (2021).","journal-title":"Arch. Dis. Child."},{"key":"95956_CR13","doi-asserted-by":"crossref","first-page":"w30092","DOI":"10.4414\/SMW.2021.w30092","volume":"151","author":"A Ulyte","year":"2021","unstructured":"Ulyte, A. et al. Evolution of SARS-CoV-2 Seroprevalence and clusters in school children from June 2020 to April 2021: prospective cohort study Ciao Corona. Swiss Med. Wkly. 151, w30092 (2021).","journal-title":"Swiss Med. Wkly."},{"issue":"12","key":"95956_CR14","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.3201\/eid2712.211465","volume":"27","author":"J Kleynhans","year":"2021","unstructured":"Kleynhans, J. et al. SARS-CoV-2 Seroprevalence in a rural and urban household cohort during first and second waves of infections, South Africa, July 2020-March 2021. Emerg. Infect. Dis. 27 (12), 3020\u20133029 (2021).","journal-title":"Emerg. Infect. Dis."},{"key":"95956_CR15","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jpeds.2021.09.029","volume":"241","author":"A Tagarro","year":"2022","unstructured":"Tagarro, A. et al. Dynamics of reverse Transcription-Polymerase chain reaction and serologic test results in children with SARS-CoV-2 infection. J. Pediatr. 241, 126\u2013132e3 (2022).","journal-title":"J. Pediatr."},{"key":"95956_CR16","doi-asserted-by":"crossref","first-page":"w30116","DOI":"10.4414\/SMW.2021.w30116","volume":"151","author":"O Beretta","year":"2021","unstructured":"Beretta, O. et al. Seroprevalence of the SARS-CoV-2 virus in the population of the Southern Switzerland (Canton Ticino) - cohort study, results at 12 months. Swiss Med. Wkly. 151, w30116 (2021).","journal-title":"Swiss Med. Wkly."},{"issue":"11","key":"95956_CR17","doi-asserted-by":"crossref","first-page":"e2135975","DOI":"10.1001\/jamanetworkopen.2021.35975","volume":"4","author":"K Zinszer","year":"2021","unstructured":"Zinszer, K. et al. Seroprevalence of SARS-CoV-2 antibodies among children in school and day care in Montreal, Canada. JAMA Netw. Open. 4 (11), e2135975 (2021).","journal-title":"JAMA Netw. Open."},{"issue":"1","key":"95956_CR18","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1503\/cmaj.202065","volume":"193","author":"JA King","year":"2021","unstructured":"King, J. A. et al. Symptoms associated with a positive result for a swab for SARS-CoV-2 infection among children in Alberta. CMAJ 193 (1), E1\u2013E9 (2021).","journal-title":"CMAJ"},{"issue":"4","key":"95956_CR19","doi-asserted-by":"crossref","first-page":"e0284046","DOI":"10.1371\/journal.pone.0284046","volume":"18","author":"EJ Doucette","year":"2023","unstructured":"Doucette, E. J. et al. A longitudinal seroepidemiology study to evaluate antibody response to SARS-CoV-2 virus infection and vaccination in children in Calgary, Canada from July 2020 to April 2022: Alberta COVID-19 childhood cohort (AB3C) study. PLoS One. 18 (4), e0284046 (2023).","journal-title":"PLoS One"},{"issue":"4","key":"95956_CR20","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","volume":"183","author":"L Piccoli","year":"2020","unstructured":"Piccoli, L. et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 Spike Receptor-Binding domain by Structure-Guided High-Resolution serology. Cell 183 (4), 1024\u20131042e21 (2020).","journal-title":"Cell"},{"issue":"1","key":"95956_CR21","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1093\/cid\/ciab1041","volume":"75","author":"L Lu","year":"2022","unstructured":"Lu, L. et al. Neutralization of severe acute respiratory syndrome coronavirus 2 Omicron variant by Sera from BNT162b2 or coronavac vaccine recipients. Clin. Infect. Dis. 75 (1), e822\u2013e826 (2022).","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"95956_CR22","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/22221751.2022.2035195","volume":"11","author":"LL Chen","year":"2022","unstructured":"Chen, L. L. et al. Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine. Emerg. Microbes Infect. 11 (1), 543\u2013547 (2022).","journal-title":"Emerg. Microbes Infect."},{"issue":"1","key":"95956_CR23","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.pep.2009.12.015","volume":"71","author":"KF Suen","year":"2010","unstructured":"Suen, K. F. et al. Transient expression of an IL-23R extracellular domain Fc fusion protein in CHO vs. HEK cells results in improved plasma exposure. Protein Expr Purif. 71 (1), 96\u2013102 (2010).","journal-title":"Protein Expr Purif."},{"issue":"4","key":"95956_CR24","first-page":"651","volume":"52","author":"DD Fraser","year":"2022","unstructured":"Fraser, D. D. et al. Cohort-Specific serological recognition of SARS-CoV-2 variant RBD antigens. Ann. Clin. Lab. Sci. 52 (4), 651\u2013662 (2022).","journal-title":"Ann. Clin. Lab. Sci."},{"issue":"11","key":"95956_CR25","doi-asserted-by":"crossref","first-page":"101267","DOI":"10.1016\/j.xcrm.2023.101267","volume":"4","author":"SC Wall","year":"2023","unstructured":"Wall, S. C. et al. SARS-CoV-2 antibodies from children exhibit broad neutralization and belong to adult public clonotypes. Cell. Rep. Med. 4 (11), 101267 (2023).","journal-title":"Cell. Rep. Med."},{"issue":"1","key":"95956_CR26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/jmv.27310","volume":"94","author":"J Fern\u00e1ndez","year":"2022","unstructured":"Fern\u00e1ndez, J. et al. Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by coronavac vaccine-induced antibodies. J. Med. Virol. 94 (1), 399\u2013403 (2022).","journal-title":"J. Med. Virol."},{"key":"95956_CR27","doi-asserted-by":"crossref","unstructured":"Joseph, G. et al. Real-World immunogenicity and reactogenicity of two doses of Pfizer-BioNTech COVID-19 vaccination in children aged 5\u201311 years. Vaccines (Basel), 10(11). (2022).","DOI":"10.3390\/vaccines10111954"},{"issue":"6","key":"95956_CR28","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4049\/immunohorizons.2200029","volume":"6","author":"A Khaitan","year":"2022","unstructured":"Khaitan, A. et al. Level and duration of IgG and neutralizing antibodies to SARS-CoV-2 in children with symptomatic or asymptomatic SARS-CoV-2 infection. Immunohorizons 6 (6), 408\u2013415 (2022).","journal-title":"Immunohorizons"},{"issue":"6","key":"95956_CR29","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S2352-4642(23)00078-0","volume":"7","author":"V Piechotta","year":"2023","unstructured":"Piechotta, V. et al. Safety and effectiveness of vaccines against COVID-19 in children aged 5\u201311 years: a systematic review and meta-analysis. Lancet Child. Adolesc. Health. 7 (6), 379\u2013391 (2023).","journal-title":"Lancet Child. Adolesc. Health"},{"issue":"1","key":"95956_CR30","doi-asserted-by":"crossref","first-page":"105783","DOI":"10.1016\/j.isci.2022.105783","volume":"26","author":"Y Chen","year":"2023","unstructured":"Chen, Y. et al. Molecular basis for antiviral activity of two pediatric neutralizing antibodies targeting SARS-CoV-2 Spike RBD. iScience 26 (1), 105783 (2023).","journal-title":"iScience"},{"key":"95956_CR31","doi-asserted-by":"crossref","unstructured":"Messiah, S. E. et al. SARS-CoV-2 serostatus and COVID-19 illness characteristics by variant time period in Non-Hospitalized children and adolescents. Child. (Basel), 10(5). (2023).","DOI":"10.3390\/children10050818"},{"issue":"1","key":"95956_CR32","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1080\/22221751.2022.2106899","volume":"11","author":"RW Poon","year":"2022","unstructured":"Poon, R. W. et al. SARS-CoV-2 IgG seropositivity after the severe Omicron wave of COVID-19 in Hong Kong. Emerg. Microbes Infect. 11 (1), 2116\u20132119 (2022).","journal-title":"Emerg. Microbes Infect."},{"issue":"8","key":"95956_CR33","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1097\/INF.0000000000003583","volume":"41","author":"A Mari","year":"2022","unstructured":"Mari, A. et al. SARS-CoV-2 Seroprevalence among School-Age children in Milan: how has it changed with the fourth pandemic Wave? Pediatr. Infect. Dis. J. 41 (8), e344\u2013e345 (2022).","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"5","key":"95956_CR34","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/jmv.27575","volume":"94","author":"G Lippi","year":"2022","unstructured":"Lippi, G., Mattiuzzi, C. & Henry, B. M. Neutralizing potency of COVID-19 vaccines against the SARS-CoV-2 Omicron (B.1.1.529) variant. J. Med. Virol. 94 (5), 1799\u20131802 (2022).","journal-title":"J. Med. Virol."},{"key":"95956_CR35","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1590\/s1678-9946202264019","volume":"64","author":"ARD Silva","year":"2022","unstructured":"Silva, A. R. D. et al. Generation of neutralizing antibodies against Omicron, gamma and delta SARS-CoV-2 variants following coronavac vaccination. Rev. Inst. Med. Trop. Sao Paulo. 64, e19 (2022).","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"issue":"2","key":"95956_CR36","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41591-023-02219-5","volume":"29","author":"JJ Lau","year":"2023","unstructured":"Lau, J. J. et al. Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population. Nat. Med. 29 (2), 348\u2013357 (2023).","journal-title":"Nat. Med."},{"issue":"7","key":"95956_CR37","doi-asserted-by":"crossref","first-page":"e18093","DOI":"10.1016\/j.heliyon.2023.e18093","volume":"9","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Clinical and humoral immune response characterization of SARS-CoV-2 Omicron BA.2.38 infection in pediatric patients. Heliyon 9 (7), e18093 (2023).","journal-title":"Heliyon"},{"key":"95956_CR38","doi-asserted-by":"crossref","first-page":"1020865","DOI":"10.3389\/fped.2023.1020865","volume":"11","author":"A Seidel","year":"2023","unstructured":"Seidel, A. et al. Serum neutralizing capacity and T-cell response against the Omicron BA.1 variant in seropositive children and their parents one year after SARS-CoV-2 infection. Front. Pediatr. 11, 1020865 (2023).","journal-title":"Front. Pediatr."},{"key":"95956_CR39","doi-asserted-by":"crossref","first-page":"100547","DOI":"10.1016\/j.lanepe.2022.100547","volume":"24","author":"ME Zaballa","year":"2023","unstructured":"Zaballa, M. E. et al. Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: a population-based study. Lancet Reg. Health Eur. 24, 100547 (2023).","journal-title":"Lancet Reg. Health Eur."},{"key":"95956_CR40","doi-asserted-by":"crossref","first-page":"11153","DOI":"10.3389\/ti.2023.11153","volume":"36","author":"I Nel","year":"2023","unstructured":"Nel, I. et al. Optimizing COVID-19 vaccination strategy in pediatric kidney transplant recipients: humoral and cellular response to SARS-CoV-2 mRNA vaccination. Transpl. Int. 36, 11153 (2023).","journal-title":"Transpl. Int."},{"key":"95956_CR41","doi-asserted-by":"crossref","unstructured":"Lee, K. J. et al. Neutralizing antibody response, safety, and efficacy of mRNA COVID-19 vaccines in pediatric patients with inflammatory bowel disease: A prospective multicenter Case-Control study. Vaccines (Basel), 10(8). (2022).","DOI":"10.3390\/vaccines10081265"},{"issue":"7","key":"95956_CR42","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/ibd\/izab207","volume":"28","author":"J Dailey","year":"2022","unstructured":"Dailey, J. et al. Antibody responses to SARS-CoV-2 after infection or vaccination in children and young adults with inflammatory bowel disease. Inflamm. Bowel Dis. 28 (7), 1019\u20131026 (2022).","journal-title":"Inflamm. Bowel Dis."},{"key":"95956_CR43","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejpn.2023.06.009","volume":"46","author":"C Kaufmann","year":"2023","unstructured":"Kaufmann, C., Morris, M. & Gombolay, G. Y. Antibody response to SARS-CoV-2 vaccination or infection in a prospective cohort of children with neuroinflammatory diseases. Eur. J. Paediatr. Neurol. 46, 30\u201334 (2023).","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"17","key":"95956_CR44","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1016\/j.vaccine.2023.03.021","volume":"41","author":"MA Perez","year":"2023","unstructured":"Perez, M. A. et al. Serologic responses to COVID-19 vaccination in children with history of multisystem inflammatory syndrome (MIS-C). Vaccine 41 (17), 2743\u20132748 (2023).","journal-title":"Vaccine"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95956-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95956-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95956-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T04:52:00Z","timestamp":1743828720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95956-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["95956"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-95956-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"16 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"MB, AL, PH, MH, and JC-A are employed by Diagnostics Biochem Canada Inc. (London, Ontario, Canada). The other authors have no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Western University, Health Sciences Research Ethics Board (HSREB Project ID: 120315), and by the Institute for Clinical Evaluative Sciences. All research was performed in accordance with relevant guidelines\/regulations. Research involving human research participants must have been performed in accordance with the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approvals"}},{"value":"Informed consent was waived by the Western University, Health Sciences Research Ethics Board (HSREB Project ID: 120315) as the research used left-over blood samples, which otherwise would have been discarded, and it was deemed safe and low risk (not obtaining consent would not cause harm p to articipants).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"11588"}}